Breakthrough chronic lymphocytic leukaemia (CLL) treatment now available for Australians
Monday, 25 February 2019
The Leukaemia Foundation welcomes the Federal Government’s announcement that the targeted cancer treatment Venetoclax (Venclexta®), will be added to Pharmaceutical Benefits Scheme (PBS) from 1 March 2019.
Venetoclax will be available in combination with rituximab for patients aged 18 years or older with relapsed or refractory chronic lymphocytic leukaemia
VOLUNTEER RECEIVES OAM FOR 30 YEARS SERVICE TO CHARITIES AND FOUNDATIONS
Wednesday, 30 January 2019
Warwick local and Leukaemia Foundation volunteer, Elaine Stewart was recognised for her vital service and support of Australians living with blood cancer.
Elaine Stewart was awarded an Order of Australia Medal for her selfless work and contribution to the Leukaemia Foundation’s Warwick Branch, as well as her local School’s Chaplaincy Committee and the Riding for the Disabled Association.
A volunteer for more than
Blood cancer patient needs could go unmet as incidence rates rise
Monday, 14 January 2019,
The number of Australians living with a blood cancer is expected to rise around 30 per cent over the next decade, according to new Leukaemia Foundation analysis as it launches World’s Greatest Shave this week.
Currently 12,800 Australians are diagnosed with a blood cancer like leukaemia, lymphoma and myeloma every
Therapeutic Goods Administration (TGA) has today approved the use of the first CAR-T therapy in Australia
Therapeutic Goods Administration (TGA) has today approved the use of the first CAR-T therapy in Australia.
A revolutionary cancer therapy that supercharges a patient’s immune cells to hunt and destroy cancer cells has been approved for use in Australia, ushering in a new era in medicine.
The TGA has
Leukaemia Foundation receives HONcode certification
Friday, 07 December 2018
The Leukaemia Foundation has been granted prestigious HONcode certification for its high standard of reliable, ethical and trustworthy health and medical content featured throughout its digital communications platforms.
The HONcode is an international standard for health and medical websites issued by the Health on the Net Foundation,
Researchers at the Peter MacCallum Cancer Centre in Melbourne believe a new combination therapy for mantle cell lymphoma could lead to a cure in almost 100 per cent of cases.
Wednesday, 05 December 2018
A story in the Sydney Morning Herald recently reported Australian researchers were closing in on a cure for the disease which was considered a “death sentence” as little as three years ago.
Peter MacCallum Cancer Centre Professor Sarah-Jane Dawson said dozens of people living with mantle
New PBS listing vital to Australians living with Acute Myeloid Leukaemia
Friday, 30 November 2018
Leukaemia Foundation CEO Mr Bill Petch has today supported the Health Minister Mr Greg Hunt’s Pharmaceuticals Benefits Scheme (PBS) listing announcement of midostaurin (Rydapt®), a targeted therapy that is considered to be an important advancement in the treatment of Acute Myeloid Leukaemia (AML) in 25 years.
Leukaemia Foundation and HSANZ Jointly Funds Three PhD Investigators
Thursday, 8 November 2018
The Leukaemia Foundation and the Haematology Society of Australia and New Zealand (HSANZ) are proud to announce the co-funding of three Australian Clinical and Science PhD investigators, whose work will focus on understanding blood cancer biology and the development of new diagnostics and precision medicines.
Position Statement: Glyphosate
Updated 17 June 2019
The Leukaemia Foundation’s CEO Bill Petch said the Leukaemia Foundation had been closely monitoring the issue of glyphosate for many years. It accepts the position of the APVMA as the Australian regulatory body, however, as the last review was undertaken in early 2017, we encourage the
Leukaemia Foundation supports WEHI’s new laboratory model to test anti-cancer drugs
Tuesday, 16 October 2018
A new model which mimics the complexity of human cancers to allow for more accurate testing of anti-cancer drugs has been developed by leading Australian researchers at the Walter and Eliza Hall Institute (WEHI) in Melbourne.
Led by PhD students Ms Margs Brennan and Dr Gemma Kelly